Synthetic Biology Approaches to Engineer Probiotics and Members of the Human Microbiota for Biomedical Applications

Annual Review of Biomedical Engineering

Volumn 20, Issue , 2018, Pages 277-300

  Bober, Josef R ^a   Beisel, Chase L ^b   Nair, Nikhil U ^a  

^a Tufts University   (United States)

^b North Carolina State University   (United States)

Author keywords

CRISPR; genetic tools; genome engineering; microbiome; probiotics

Indexed keywords

HEALTH; LACTIC ACID; MEDICAL APPLICATIONS;

CRISPR; GENETIC TOOLS; GENOME ENGINEERING; MICROBIOME; PROBIOTICS;

BACTERIA;

PROBIOTIC AGENT; LACTIC ACID;

BACTEROIDES; BIFIDOBACTERIALES; BIOMEDICAL ENGINEERING; CELL FUNCTION; COMMENSAL; DISEASES; GENE EXPRESSION; GENETIC ENGINEERING; GENOME; HOST PATHOGEN INTERACTION; HUMAN; LACTIC ACID BACTERIUM; MICROFLORA; NONHUMAN; REVIEW; SYNTHETIC BIOLOGY; ANIMAL; CHEMISTRY; CRISPR CAS SYSTEM; GENE EDITING; GENOMICS; IMMUNE SYSTEM; PROCEDURES;

ANIMALS; BACTEROIDES; CRISPR-CAS SYSTEMS; GENE EDITING; GENETIC ENGINEERING; GENOMICS; HUMANS; IMMUNE SYSTEM; LACTIC ACID; MICROBIOTA; PROBIOTICS; SYNTHETIC BIOLOGY;

EID: 85047975174     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-062117-121019     Document Type: Review

References (150)

1. Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, et al. 2012. Structure, function and diversity of the healthy human microbiome. Nature 486:207-14
2. Belizario JE, Napolitano M. 2015. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Front. Microbiol. 6:1050
3. Lau JT, Whelan FJ, Herath I, Lee CH, Collins SM, et al. 2016. Capturing the diversity of the human gut microbiota through culture-enriched molecular profiling. Genome Med. 8:72
4. Langdon A, Crook N, Dantas G. 2016. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 8:39
5. Didari T, Mozaffari S, Nikfar S, Abdollahi M. 2015. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J. Gastroenterol. 21:3072-84
6. Verna EC, Lucak S. 2010. Use of probiotics in gastrointestinal disorders: what to recommend? Ther. Adv. Gastroenterol. 3:307-19
7. Tsai YT, Cheng PC, Pan TM. 2014. Anti-obesity effects of gut microbiota are associated with lactic acid bacteria. Appl. Microbiol. Biotechnol. 98:1-10
8. Brennan CA, Garrett WS. 2016. Gut microbiota, inflammation, and colorectal cancer. Annu. Rev. Microbiol. 70:395-411
9. Moos WH, Faller DV, Harpp DN, Kanara I, Pernokas J, et al. 2016. Microbiota and neurological disorders: a gut feeling. Biores. Open Access 5:137-45
10. Brandwein M, Steinberg D, Meshner S. 2016. Microbial biofilms and the human skin microbiome. npj Biofilms Microbiomes 2:3
11. Egert M, Simmering R, Riedel CU. 2017. The association of the skin microbiota with health, immunity, and disease. Clin. Pharmacol. Ther. 102:62-69
12. Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner ACR, et al. 2010. The human oral microbiome. J. Bacteriol. 192:5002-17
13. Kilian M, Chapple ILC,HannigM,Marsh PD,Meuric V, et al. 2016. The oral microbiome-an update for oral healthcare professionals. Br. Dent. J. 221:657-66
14. Gopinath S, Iwasaki A. 2015. Cervicovaginal microbiota: Simple is better. Immunity 42:790-91
15. Sanders ME, Gibson GR, Gill HS, Guarner F. 2007. Probiotics: their potential to impact human health. Issue pap. 36, Counc. Agric. Sci. Technol., Ames, IA
16. Ballal SA, Veiga P, Fenn K, MichaudM, Kim JH, et al. 2015. Host lysozyme-mediated lysis of Lactococcus lactis facilitates delivery of colitis-attenuating superoxide dismutase to inflamed colons. PNAS 112:7803-8
17. Fedorak RN. 2010. Probiotics in the management of ulcerative colitis. Gastroenterol. Hepatol. 6:688-90
18. Prantera C. 2006. Probiotics for Crohn's disease: What have we learned? Gut 55:757-59
19. vanNood E, Vrieze A, NieuwdorpM, Fuentes S, Zoetendal EG, et al. 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368:407-15
20. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, et al. 2013. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: "rePOOPulating" the gut. Microbiome 1:3
21. Ullah MW, Khattak WA, Ul-Islam M, Khan S, Park JK. 2016. Metabolic engineering of synthetic cell-free systems: strategies and applications. Biochem. Eng. J. 105:391-405
22. Cameron DE, Bashor CJ, Collins JJ. 2014. A brief history of synthetic biology. Nat. Rev. Microbiol. 12:381-90
23. Marchand N, CollinsCH. 2016. Synthetic quorum sensing and cell-cell communication in gram-positive Bacillus megaterium. ACS Synth. Biol. 5:597-606
24. Brophy JAN, Voigt CA. 2014. Principles of genetic circuit design. Nat. Methods 11:508-20
25. Hsu PD, Lander ES, Zhang F. 2014. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:1262-78
26. Park M, Tsai SL, Chen W. 2013. Microbial biosensors: engineered microorganisms as the sensing machinery. Sensors 3:5777-95
27. Rong G, Corrie SR, Clark HA. 2017. In vivo biosensing: progress and perspectives. ACS Sens. 2:327-38
28. Cribby S, Taylor M, Reid G. 2008. Vaginal microbiota and the use of probiotics. Interdiscip. Perspect. Infect. Dis. 2008:256490
29. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, et al. 2013. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341:1241214
30. Lagier J-C, Khelaifia S, Alou MT, Ndongo S, Dione N, et al. 2016. Culture of previously uncultured members of the human gut microbiota by culturomics. Nat. Microbiol. 1:1-8
31. Waller MC, Bober JR, Nair NU, Beisel CL. 2017. Toward a genetic tool development pipeline for host-associated bacteria. Curr. Opin. Microbiol. 38:156-64
32. Spath K, Hein S, Grabherr R. 2012. Direct cloning in Lactobacillus plantarum: Electroporation with non-methylated plasmid DNA enhances transformation efficiency and makes shuttle vectors obsolete. Microb. Cell Fact. 11:141
33. van Houte S, Buckling A,Westra ER. 2016. Evolutionary ecology of prokaryotic immune mechanisms. Microbiol. Mol. Biol. Rev. 80:745-63
34. Roberts RJ, Vincze T, Posfai J, Macelis D. 2015. REBASE-A database for DNA restriction and modification: enzymes, genes and genomes. Nucleic Acids Res. 43:D298-99
35. Kok J, Van Der Vossen JMBM, Venema G. 1984. Construction of plasmid cloning vectors for lactic streptococci which also replicate in Bacillus subtilis and Escherichia coli. Appl. Environ.Microbiol. 48:726-31
36. De VosWM. 1987. Gene cloning and expression in lactic streptococci. FEMS Microbiol. Lett. 46:281-95
37. Leenhouts KJ, Kok J, Venema G. 1991. Lactococcal plasmid pWVO1 as an integration vector for lactococci. Appl. Environ. Microbiol. 57:2562-67
38. Fang F, O'Toole PW. 2009. Genetic tools for investigating the biology of commensal lactobacilli. Front. Biosci. 14:3111-27
39. Landete JM. 2017. A review of food-grade vectors in lactic acid bacteria: from the laboratory to their application. Crit. Rev. Biotechnol. 37:296-308
40. Missich R, Sgorbati B, LeBlanc DJ. 1994. Transformation of Bifidobacterium longum with pRM2, a constructed Escherichia coli-B. longum shuttle vector. Plasmid 32:208-11
41. MatsumuraH, Takeuchi A, Kano Y. 1997. Construction of Escherichia coli-Bifidobacterium longum shuttle vector transforming B. longum 105-A and 108-A. Biosci. Biotechnol. Biochem. 61:1211-12
42. A lvarez-Martin P, Flo rez AB, Margolles A, Del Solar G, Mayo B. 2008. Improved cloning vectors for bifidobacteria, based on the Bifidobacterium catenulatum pBC1 replicon. Appl. Environ.Microbiol. 74:4656-65
43. Garrigues-Jeanjean N, Wittmer A, Ouriet M, Duval-Iflah Y. 1999. Transfer of the shuttle vector pRRI207 between Escherichia coli and Bacteroides spp. in vitro and in vivo in the digestive tract of axenic mice and in gnotoxenic mice inoculated with a human microflora. FEMS Microbiol. Ecol. 29:33-43
44. TauerC,Heinl S, Egger E,Heiss S, Grabherr R. 2014. Tuning constitutive recombinant gene expression in Lactobacillus plantarum. Microb. Cell Fact. 13:150
45. Mimee M, Tucker AC, Voigt CA, Lu TK. 2015. Programming a human commensal bacterium, Bacteroides thetaiotaomicron, to sense and respond to stimuli in the murine gut microbiota. Cell Syst. 1:62-71
46. Mierau I, Kleerebezem M. 2005. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl. Microbiol. Biotechnol. 68:705-17
47. Kaswurm V, Nguyen T-T, Maischberger T, Kulbe KD, Michlmayr H. 2013. Evaluation of the food grade expression systems NICE and pSIP for the production of 2,5-diketo-D-gluconic acid reductase from Corynebacterium glutamicum. AMB Express 3:7
48. Mathiesen G, Sørvig E, Blatny J, Naterstad K, Axelsson L, Eijsink VGH. 2004. High-level gene expression in Lactobacillus plantarum using a pheromone-regulated bacteriocin promoter. Lett. Appl. Microbiol. 39:137-43
49. Heiss S, Hormann A, Tauer C, Sonnleitner M, Egger E, et al. 2016. Evaluation of novel inducible promoter/repressor systems for recombinant protein expression in Lactobacillus plantarum. Microb. Cell Fact. 15:50
50. Horn N, Carvalho AL, Overweg K,Wegmann U, Carding SR, Stentz R. 2016. A novel tightly regulated gene expression system for the human intestinal symbiont Bacteroides thetaiotaomicron. Front. Microbiol. 7:1080
51. Bosma EF, Forster J, Nielsen AT. 2017. Lactobacilli and pediococci as versatile cell factories-evaluation of strain properties and genetic tools. Biotechnol. Adv. 35:419-42
52. Kushwaha M, Salis HM. 2015. A portable expression resource for engineering cross-species genetic circuits and pathways. Nat. Commun. 6:7832
53. Allain T, Mansour NM, Bahr MMA,Martin R, Florent I, et al. 2016. A new lactobacilli in vivo expression system for the production and delivery of heterologous proteins at mucosal surfaces. FEMS Microbiol. Lett. 363:fnw117
54. Schneewind O, Missiakas D. 2014. Sec-secretion and sortase-mediated anchoring of proteins in grampositive bacteria. Biochim. Biophys. Acta 1843:1687-97
55. Dieye Y, Usai S, Clier F, Gruss A, Piard J. 2001. Design of a protein-targeting system for lactic acid bacteria. J. Bacteriol. 183:4157-66
56. Le Loir Y, Nouaille S, Commissaire J, Bretigny L, Langella P. 2001. Signal peptide and propeptide optimization for heterologous protein secretion in Lactococcus lactis. Appl. Environ. Microbiol. 67:4119-27
57. Mathiesen G, Sveen A, Piard J-C, Axelsson L, Eijsink VGH. 2008. Heterologous protein secretion by Lactobacillus plantarum using homologous signal peptides. J. Appl. Microbiol. 105:215-26
58. Zadravec P, Strukelj B, Berlec A. 2015. Heterologous surface display on lactic acid bacteria: non-GMO alternative? Bioengineered 6:179-83
59. Michon C, Langella P, Eijsink VGH, Mathiesen G, Chatel JM. 2016. Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications. Microb. Cell Fact. 15:70
60. Dalia AB,McDonough E, Camilli A. 2014. Multiplex genome editing by natural transformation. PNAS 111:8937-42
61. van Pijkeren JP, Britton RA. 2012. High efficiency recombineering in lactic acid bacteria. Nucleic Acids Res. 40:e76
62. Lambert JM, Bongers RS, Kleerebezem M. 2007. Cre-lox-based system for multiple gene deletions and selectable-marker removal in Lactobacillus plantarum. Appl. Environ. Microbiol. 73:1126-35
63. JiangW, BikardD, Cox D, Zhang F,Marraffin LA. 2013. CRISPR-assisted editing of bacterial genomes. Nat Biotechnol. 31:233-39
64. van Pijkeren JP, Britton RA. 2014. Precision genome engineering in lactic acid bacteria. Microb. Cell Fact. 13(Suppl. 1):S10
65. Oh JH, van Pijkeren JP. 2014. CRISPR-Cas9-assisted recombineering in Lactobacillus reuteri. Nucleic Acids Res. 42:e131
66. Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS. 2013. CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat. Protoc. 8:2180-96
67. Danino T, Prindle A, Kwong GA, Skalak M, Li H, et al. 2015. Programmable probiotics for detection of cancer in urine. Sci. Transl. Med. 7:289ra84
68. Ou B, Yang Y, Tham WL, Chen L, Guo J. 2016. Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application. Appl. Microbiol. Biotechnol. 100:8693-99
69. Stritzker J,Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA. 2007. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int. J. Med. Microbiol. 297:151-62
70. Gasteiger G, D'Osualdo A, Schubert DA, Weber A, Bruscia EM, Hartl D. 2017. Cellular innate immunity: an old game with new players. J. Innate Immun. 9:111-25
71. Wyszy nska A, Kobierecka P, Bardowski J, Jagusztyn-Krynicka EK. 2015. Lactic acid bacteria-20 years exploring their potential as live vectors for mucosal vaccination. Appl. Microbiol. Biotechnol. 99:2967-77
72. Tarahomjoo S. 2012. Development of vaccine delivery vehicles based on lactic acid bacteria. Mol. Biotechnol. 51:183-99
73. Wells JM, Mercenier A. 2008. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat. Rev. Microbiol. 6:349-62
74. Cronin M, Morrissey D, Rajendran S, El Mashad SM, van Sinderen D, et al. 2010. Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Mol. Ther. 18:1397-407
75. Hanson ML, Hixon JA, Li W, Felber BK, Anver MR, et al. 2014. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 146:210-21
76. MeisterG, Tuschi T. 2004. Mechanisms of gene silencing by double-stranded RNA. Nature 431:343-49
77. Spisni E, ValeriiMC, De Fazio L, Cavazza E, Borsetti F, et al. 2015. Cyclooxygenase-2 silencing for the treatment of colitis: a combined in vivo strategy based on RNA interference and engineered Escherichia coli. Mol. Ther. 23:278-89
78. Christophe M, Kuczkowska K, Langella P, Eijsink VGH, Mathiesen G, Chatel J-M. 2015. Surface display of an anti-DEC-205 single chain Fv fragment in Lactobacillus plantarum increases internalization and plasmid transfer to dendritic cells in vitro and in vivo. Microb. Cell Fact. 14:95
79. Takei S, Omoto C, KitagawaK,Morishita N, KatayamaT, et al. 2014. Oral administration of genetically modified Bifidobacterium displayingHCV-NS3multi-epitope fusion protein could induce anHCV-NS3-specific systemic immune response in mice. Vaccine 32:3066-74
80. Frykberg RG, Banks J. 2015. Challenges in the treatment of chronic wounds. Adv. Wound Care 4:560-82
81. Kim J, Amar S. 2006. Periodontal disease and systemic conditions: a bidirectional relationship. Odontology 94:10-21
82. Bai A-P, Ouyang Q. 2006. Probiotics and inflammatory bowel diseases. Postgrad. Med. J. 82:376-82
83. Ratjen FA. 2009. Cystic fibrosis: pathogenesis and future treatment strategies. Respir. Care 54:595-605
84. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-50
85. Geldart K, Borrero J, Kaznessis YN. 2015. Chloride-inducible expression vector for delivery of antimicrobial peptides targeting antibiotic-resistant Enterococcus faecium. Appl. Environ. Microbiol. 81:3889-97
86. Brurberg MB, Nes IF, Eijsink VG. 1997. Pheromone-induced production of antimicrobial peptides in Lactobacillus. Mol. Microbiol. 26:347-60
87. Jones SE, Versalovic J. 2009. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and antiinflammatory factors. BMC Microbiol. 9:35
88. Roelofs KG, CoyneMJ, Gentyala RR, Chatzidaki-LivanisM, Comstock LE. 2016. Bacteroidales secreted antimicrobial proteins target surface molecules necessary for gut colonization and mediate competition in vivo. mBio 7:e0155
89. Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J. 2008. Humanderived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 14:166-71
90. van Pijkeren J-P,Neoh KM, Sirias D, Findley AS, Britton RA. 2012. Exploring optimization parameters to increase ssDNA recombineering in Lactococcus lactis and Lactobacillus reuteri. Bioengineered 3:209-17
91. Borrero J, Chen Y, Dunny GM, Kaznessis YN. 2015. Modified lactic acid bacteria detect and inhibit multiresistant enterococci. ACS Synth. Biol. 4:299-306
92. Hwang IY, Tan MH, Koh E, Ho CL, Poh CL, Chang MW. 2014. Reprogramming microbes to be pathogen-seeking killers. ACS Synth. Biol. 3:228-37
93. Hwang IY, Koh E, Wong A, March JC, Bentley WE, et al. 2017. Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. Nat. Commun. 8:15028
94. Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, et al. 2014. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. PNAS 111:7421-26
95. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, et al. 2009. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. PNAS 106:3698-703
96. Sanz Y, Olivares M, Moya-Perez A , Agostoni C. 2015. Understanding the role of gut microbiome in metabolic disease risk. Pediatr. Res. 77:236-44
97. Krishnan S, Alden N, Lee K. 2015. Pathways and functions of gut microbiota metabolism impacting host physiology. Curr. Opin. Biotechnol. 36:137-45
98. Le Barz M, Anhe FF, Varin TV,DesjardinsY,Levy E, et al. 2015. Probiotics as complementary treatment for metabolic disorders. Diabetes Metab. J. 39:291-303
99. Rhimi M, Bermudez-Humaran LG, Huang Y, Boudebbouze S, Gaci N, et al. 2015. The secreted L-arabinose isomerase displays anti-hyperglycemic effects in mice. Microb. Cell Fact. 14:204
100. Duan FF, Liu JH, March JC. 2015. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 64:1794-803
101. Mauricio MD, Serna E, Fernandez-Murga ML, Portero J, Aldasoro M, et al. 2017. Bifidobacterium pseudocatenulatum CECT 7765 supplementation restores altered vascular function in an experimental model of obese mice. Int. J. Med. Sci. 14:444-51
102. Ojetti V, Gigante G, Gabrielli M, Ainora ME,Mannocci A, et al. 2010. The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial. Eur. Rev. Med. Pharmacol. Sci. 14:163-70
103. Durrer KE, Allen MS, Hunt von Herbing I. 2017. Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU. PLOS ONE 12:e0176286
104. Sasikumar P, Gomathi S, Anbazhagan K, Abhishek A, Paul E, et al. 2014. Recombinant Lactobacillus plantarum expressing and secreting heterologous oxalate decarboxylase prevents renal calcium oxalate stone deposition in experimental rats. J. Biomed. Sci. 21:86
105. Daeffler KN, Galley JD, Sheth RU, Ortiz-Velez LC, Bibb CO, et al. 2017. Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation. Mol. Syst. Biol. 13:923
106. Benbouziane B, Ribelles P, Aubry C,Martin R, Kharrat P, et al. 2013. Development of a stress-inducible controlled expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J. Biotechnol. 168:120-29
107. Landete JM, Medina M, Arques JL. 2016. Fluorescent reporter systems for tracking probiotic lactic acid bacteria and bifidobacteria. World J. Microbiol. Biotechnol. 32:119
108. Karimi S, Ahl D, Vagesj o E, Holm L, Phillipson M, et al. 2016. In vivo and in vitro detection of luminescent and fluorescent Lactobacillus reuteri and application of red fluorescent mCherry for assessing plasmid persistence. PLOS ONE 11:e0151969
109. Berlec A, Zavrsnik J, ButinarM,Turk B, Strukelj B. 2015. In vivo imaging of Lactococcus lactis, Lactobacillus plantarum and Escherichia coli expressing infrared fluorescent protein in mice. Microb. Cell Fact. 14:181
110. Farzadfard F, Lu TK. 2014. Synthetic biology. Genomically encoded analog memory with precise in vivo DNA writing in living cell populations. Science 346:1256272
111. Bonnet J, Subsoontorn P, Endy D. 2012. Rewritable digital data storage in live cells via engineered control of recombination directionality. PNAS 109:8884-89
112. Pandey KR, Naik SR, Vakil BV. 2015. Probiotics, prebiotics and synbiotics-A review. J. Food Sci. Technol. 52:7577-87
113. Beisel CL,Gomaa AA, Barrangou R. 2014. ACRISPR design for next-generation antimicrobials. Genome Biol. 15:516
114. Bikard D, Euler CW, JiangW, Nussenzweig PM, Goldberg GW, et al. 2014. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol. 32:1146-50
115. Gomaa AA, Klumpe HE, Luo ML, Selle K, Barrangou R, Beisel CL. 2014. Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. mBio 5:e00928
116. Citorik RJ, Mimee M, Lu TK. 2014. Sequence-specific antimicrobials using efficiently delivered RNAguided nucleases. Nat. Biotechnol. 32:1141-45
117. Park JY, Moon BY, Park JW, Thornton JA, Park YH, Seo KS. 2017. Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus. Sci. Rep. 7:1-13
118. GorenM, Yosef I, Qimron U. 2017. Sensitizing pathogens to antibiotics using the CRISPR-Cas system. Drug Resist. Update 30:1-6
119. Brito IL, Yilmaz S, Huang K, Xu L, Jupiter SD, et al. 2016. Mobile genes in the human microbiome are structured from global to individual scales. Nature 535:435-39
120. Sheth RU, Cabral V, Chen SP, Wang HH. 2016. Manipulating bacterial communities by in situ microbiome engineering. Trends Genet. 32:189-200
121. Tannock GW. 1987. Conjugal transfer of plasmid pAMβ1 inLactobacillus reuteri and between lactobacilli and Enterococcus faecalis. Appl. Environ. Microbiol. 53:2693-95
122. McConnell MA,Mercer AA, Tannock GW. 1991. Transfer of plasmid pAMβl between members of the normal microflora inhabiting the murine digestive tract and modification of the plasmid in a Lactobacillus reuteri host. Microb. Ecol. Health Dis. 4:343-55
123. Netherwood T, Bowden R, Harrison P, O'Donnell G, Parker DS, Gilbert HJ. 1999. Gene transfer in the gastrointestinal tract. Appl. Environ. Microbiol. 65:5139-41
124. Shintani M, Sanchez ZK, Kimbara K. 2015. Genomics of microbial plasmids: classification and identification based on replication and transfer systems and host taxonomy. Front. Microbiol. 6:242
125. Chen Y, Lin Y, Davis KM,Wang Q, Rnjak-Kovacina J, et al. 2015. Robust bioengineered 3D functional human intestinal epithelium. Sci. Rep. 5:13708
126. Arnold JW, Roach J, Azcarate-Peril MA. 2016. Emerging technologies for gut microbiome research. Trends Microbiol. 24:887-901
127. Yaung SJ, Church GM, Wang HH. 2014. Recent progress in engineering human-associated microbiomes. Methods Mol. Biol. 1151:3-25
128. Hazebrouck S, Oozeer R, Adel-Patient K, Langella P, Rabot S, et al. 2006. Constitutive delivery of bovine β-lactoglobulin to the digestive tracts of gnotobiotic mice by engineered Lactobacillus casei. Appl. Environ. Microbiol. 72:7460-67
129. Rooks MG, Garrett WS. 2016. Gut microbiota, metabolites and host immunity. Nat. Rev. Immunol. 16:341-52
130. Fiebiger U, Bereswill S, Heimesaat MM. 2016. Dissecting the interplay between intestinal microbiota and host immunity in health and disease: lessons learned from germfree and gnotobiotic animal models. Eur. J. Microbiol. Immunol. 6:253-71
131. MacKenzie DA, Jeffers F, ParkerML, Vibert-Vallet A, Bongaerts RJ, et al. 2010. Strain-specific diversity of mucus-binding proteins in the adhesion and aggregation properties of Lactobacillus reuteri. Microbiology 156:3368-78
132. Jourova L, Anzenbacher P, Liskova B, Matuskova Z, Hermanova P, et al. 2017. Colonization by nonpathogenic bacteria alters mRNA expression of cytochromes P450 in originally germ-free mice. Folia Microbiol. 62:463-69
133. Ito R, Takahashi T, Katano I, Ito M. 2012. Current advances in humanized mouse models. Cell. Mol. Immunol. 9:208-14
134. Nguyen TLA, Vieira-Silva S, Liston A, Raes J. 2015. How informative is the mouse for human gut microbiota research? Dis. Model. Mech. 8:1-16
135. Arrieta M, Walter J, Finlay BB. 2016. Forum human microbiota-associated mice: a model with challenges. Cell Host Microbe 19:575-78
136. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, et al. 2003. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin Nat. Biotechnol. 21:785-89
137. Mandell DJ, Lajoie MJ,Mee MT, Takeuchi R, Kuznetsov G, et al. 2015. Biocontainment of genetically modified organisms by synthetic protein design. Nature 518:55-60
138. Chan CTY, Lee JW, Cameron DE, Bashor CJ, Collins JJ. 2015. "Deadman" and "Passcode" microbial kill switches for bacterial containment. Nat. Chem. Biol. 12:82-86
139. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, et al. 2006. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 118:511-21
140. O'Connor EM. 2013. The role of gut microbiota in nutritional status. Curr. Opin. Clin. Nutr. Metab. Care 16:509-16
141. Kali A. 2015. Human microbiome engineering: the future and beyond. J. Clin. Diagn. Res. 9:1-4
142. Krumbeck JA, Marsteller NL, Frese SA, Peterson DA, Ramer-Tait AE, et al. 2016. Characterization of the ecological role of genes mediating acid resistance in Lactobacillus reuteri during colonization of the gastrointestinal tract. Environ. Microbiol. 18:2172-84
143. Lee SM, Donaldson GP, Mikulski Z, Boyajian S, Ley K, Mazmanian SK. 2013. Bacterial colonization factors control specificity and stability of the gut microbiota. Nature 501:426-29
144. Etzold S, Kober OI, Mackenzie DA, Tailford LE, Gunning AP, et al. 2014. Structural basis for adaptation of lactobacilli to gastrointestinal mucus. Environ. Microbiol. 16:888-903
145. Coyne MJ, Chatzidaki-Livanis M, Paoletti LC, Comstock LE. 2008. Role of glycan synthesis in colonization of the mammalian gut by the bacterial symbiont Bacteroides fragilis. PNAS 105:13099-104
146. Etzold S, Mackenzie DA, Jeffers F,Walshaw J, Roos S, et al. 2014. Structural andmolecular insights into novel surface-exposed mucus adhesins from Lactobacillus reuteri human strains. Mol. Microbiol. 92:543-56
147. Angelakis E, Armougom F, Carriere F, Bachar D, Laugier R, et al. 2015. A metagenomic investigation of the duodenal microbiota reveals links with obesity. PLOS ONE 10:e0137784
148. Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, et al. 2006. Molecular analysis of the bacterial microbiota in the human stomach. PNAS 103:732-37
149. Shin NR, Whon TW, Bae JW. 2015. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 33:496-503
150. Sankar SA, Lagier J-C, Pontarotti P, Raoult D, Fournier P-E. 2015. The human gut microbiome, a taxonomic conundrum. Syst. Appl. Microbiol. 38:276-86